News June 2022

Natrox^® Wound Care Expands into the Digital Arena With Natrox^® IQ

Natrox^® Wound Care recently announced its expansion into the digital arena with the launch of Natrox^® IQ. The company says its advanced wound hub is a digital service designed specifically for wound care teams to help manage caseloads more effectively. Clinicians can achieve consistency when capturing and documenting patient wound data. Available now through distribution partners in Hong Kong and Malaysia, the company says Natrox^® IQ is designed to make wound documentation easier.

The advanced digital platform offers a central, cloud-based hub where clinical teams across various locations or disciplines can capture and access up-to-date information on wound care patients, according to a press release. The platform can also connect to a third party software to measure wound size and depth digitally, enabling greater accuracy. It also allows clinicians to oversee wound progression remotely via a telehealth feature which includes video conferencing and SMS messaging. This can help reduce nonessential clinic visits and increase convenience for both patients and clinicians.

Click here for more info.

FDA Grants Breakthrough Device Status to Net Health’s Tissue Analytics for Wound Care

Net Health, a provider of specialty electronic healthcare record (EHR) and predictive analytics software, announced recently that Tissue Analytics, the company’s AI-powered wound imaging and analysis software, has been granted Breakthrough Device Status by the U.S. Food & Drug Administration (FDA). The company says Tissue Analytics received the rare designation because of its novel diagnostic algorithms. The company believes the FDA designation represents the first time an EHR company has been granted such designation.

Breakthrough Status indicates that the FDA believes the Company’s novel diagnostic Software as a Medical Device (SaMD) could provide more effective treatment or diagnosis of a life-threatening or debilitating condition, such as hospital-acquired pressure injuries (HAPIs), venous and diabetic foot ulcers and other non-healing wounds. Breakthrough Status is granted when a device meets two or more of the following criteria: no other approved or cleared alternatives exist; the device offers significant advantages over existing approved or cleared alternatives; or the device availability is in the patient’s best interest.

Click here for more info.

MolecuLight Receives Point-of-Care Wound Imaging Devices Agreement With Premier, Inc.

MolecuLight Corp. recently announced it has been awarded a new group purchasing agreement with Premier, Inc., uniting more than 4,400 U.S. hospitals and 225,000 other providers. The MolecuLight i:X^® and DX^™ wound imaging devices were also awarded Premier’s Technology Breakthrough designation, signifying innovative products that are helping clinicians to improve the state of wound care and ultimately to improve outcomes.
 
Effective June 1, 2022, the new contract allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for MolecuLight’s point-of-care wound imaging devices as part of the Skin Integrity category of products.
The MolecuLight imaging devices are the only FDA-approved devices that allow clinicians to visualize the presence, location, and load of bacteria (>10⁴ CFU/g) in wounds in real-time, notes the company.
 
Click here for more info.